These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 10418797)

  • 1. Inhibition of platelet aggregation by abciximab but not by aspirin can be detected by a new point-of-care test, the hemostatus.
    Coiffic A; Cazes E; Janvier G; Forestier F; Lanza F; Nurden A; Nurden P
    Thromb Res; 1999 Jul; 95(2):83-91. PubMed ID: 10418797
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative real-time effects on platelet adhesion and aggregation under flowing conditions of in vivo aspirin, heparin, and monoclonal antibody fragment against glycoprotein IIb-IIIa.
    Turner NA; Moake JL; Kamat SG; Schafer AI; Kleiman NS; Jordan R; McIntire LV
    Circulation; 1995 Mar; 91(5):1354-62. PubMed ID: 7867173
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Induction of fibrinogen binding and platelet aggregation as a potential intrinsic property of various glycoprotein IIb/IIIa (alphaIIbbeta3) inhibitors.
    Peter K; Schwarz M; Ylänne J; Kohler B; Moser M; Nordt T; Salbach P; Kübler W; Bode C
    Blood; 1998 Nov; 92(9):3240-9. PubMed ID: 9787160
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Labeling of the internal pool of GP IIb-IIIa in platelets by c7E3 Fab fragments (abciximab): flow and endocytic mechanisms contribute to the transport.
    Nurden P; Poujol C; Durrieu-Jais C; Winckler J; Combrié R; Macchi L; Bihour C; Wagner C; Jordan R; Nurden AT
    Blood; 1999 Mar; 93(5):1622-33. PubMed ID: 10029591
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of GP IIb/IIIa receptor monoclonal antibody (7E3), heparin, and aspirin in an ex vivo canine arteriovenous shunt model of stent thrombosis.
    Makkar RR; Litvack F; Eigler NL; Nakamura M; Ivey PA; Forrester JS; Shah PK; Jordan RE; Kaul S
    Circulation; 1997 Feb; 95(4):1015-21. PubMed ID: 9054765
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rapid and simple platelet function assay to assess glycoprotein IIb/IIIa receptor blockade.
    Coller BS; Lang D; Scudder LE
    Circulation; 1997 Feb; 95(4):860-7. PubMed ID: 9054743
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rapid assessment of platelet function with a modified whole-blood aggregometer in percutaneous transluminal coronary angioplasty patients receiving anti-GP IIb/IIIa therapy.
    Mascelli MA; Worley S; Veriabo NJ; Lance ET; Mack S; Schaible T; Weisman HF; Jordan RE
    Circulation; 1997 Dec; 96(11):3860-6. PubMed ID: 9403608
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incomplete inhibition of platelet aggregation and glycoprotein IIb-IIIa receptor blockade by abciximab: importance of internal pool of glycoprotein IIb-IIIa receptors.
    Gawaz M; Ruf A; Pogatsa-Murray G; Dickfeld T; Rüdiger S; Taubitz W; Fischer J; Müller I; Meier D; Patscheke H; Schömig A
    Thromb Haemost; 2000 Jun; 83(6):915-22. PubMed ID: 10896249
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of platelets and white blood cells and antiplatelet agent C7E3 (Reopro) on a new test of PAF procoagulant activity of whole blood.
    Despotis GJ; Ikonomakou S; Levine V; Joiner-Maier D; Santoro SA; Joist JH
    Thromb Res; 1997 May; 86(3):205-19. PubMed ID: 9175242
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quantification of abciximab-induced platelet inhibition is assay dependent: a comparative study in patients undergoing percutaneous coronary intervention.
    Furman MI; Kereiakes DJ; Krueger LA; Mueller MN; Broderick TM; Schneider JF; Howard WL; Fox ML; Barnard MR; Frelinger AL; Michelson AD
    Am Heart J; 2003 Feb; 145(2):e6. PubMed ID: 12595861
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The glycoprotein IIb/IIIa antagonist c7E3 inhibits platelet aggregation in the presence of heparin-associated antibodies.
    Liem TK; Teel R; Shukla S; Silver D
    J Vasc Surg; 1997 Jan; 25(1):124-30. PubMed ID: 9013915
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative studies of a humanized anti-glycoprotein IIb/IIIa monoclonal antibody, YM337, and abciximab on in vitro antiplatelet effect and binding properties.
    Suzuki K; Sato K; Kamohara M; Kaku S; Kawasaki T; Yano S; Iizumi Y
    Biol Pharm Bull; 2002 Aug; 25(8):1006-12. PubMed ID: 12186399
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Upregulation of GP IIb/IIIa receptors during platelet activation: influence on efficacy of receptor blockade.
    Matzdorff A; Voss R
    Thromb Res; 2006; 117(3):307-14. PubMed ID: 15894353
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro measurement of platelet glycoprotein IIb/IIIa receptor blockade by abciximab: interindividual variation and increased platelet secretion.
    Rossi F; Rossi E; Pareti FI; Colli S; Tremoli E; Gallo L
    Haematologica; 2001 Feb; 86(2):192-8. PubMed ID: 11224490
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glycoprotein IIb/IIIa and P2Y12 receptor antagonists yield additive inhibition of platelet aggregation, granule secretion, soluble CD40L release and procoagulant responses.
    Judge HM; Buckland RJ; Holgate CE; Storey RF
    Platelets; 2005 Nov; 16(7):398-407. PubMed ID: 16236601
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of the glycoprotein IIb/IIIa receptor antagonist c7E3 Fab and anticoagulants on platelet aggregation and thrombin potential under high coagulant challenge in vitro.
    Koestenberger M; Gallistl S; Cvirn G; Roschitz B; Muntean W
    Blood Coagul Fibrinolysis; 2000 Jul; 11(5):425-32. PubMed ID: 10937803
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibitory effects of glycoprotein IIb/IIIa antagonists and aspirin on the release of soluble CD40 ligand during platelet stimulation.
    Nannizzi-Alaimo L; Alves VL; Phillips DR
    Circulation; 2003 Mar; 107(8):1123-8. PubMed ID: 12615789
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of antiplatelet drugs, heparin, and preanalytical variables on platelet function detected by the platelet function analyzer (PFA-100).
    Kottke-Marchant K; Powers JB; Brooks L; Kundu S; Christie DJ
    Clin Appl Thromb Hemost; 1999 Apr; 5(2):122-30. PubMed ID: 10725993
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Shear-induced platelet aggregation is inhibited by in vivo infusion of an anti-glycoprotein IIb/IIIa antibody fragment, c7E3 Fab, in patients undergoing coronary angioplasty.
    Konstantopoulos K; Kamat SG; Schafer AI; Bañez EI; Jordan R; Kleiman NS; Hellums JD
    Circulation; 1995 Mar; 91(5):1427-31. PubMed ID: 7867183
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The GP IIb/IIIa inhibitor abciximab (ReoPro) decreases activation and interaction of platelets and leukocytes during in vitro cardiopulmonary bypass simulation.
    Straub A; Wendel HP; Azevedo R; Ziemer G
    Eur J Cardiothorac Surg; 2005 Apr; 27(4):617-21. PubMed ID: 15784360
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.